Gregory M. Weinhoff - 01 Feb 2026 Form 4 Insider Report for Centessa Pharmaceuticals plc (CNTA)

Role: Chief Business Officer
Signature: /s/ Raphael Deferiere, attorney-in-fact
Issuer symbol: CNTA
Transactions as of: 01 Feb 2026
Net transactions value: -$347,862
Form type: 4
Filing time: 03 Feb 2026, 18:57:58 UTC
Previous filing: 25 Jul 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Weinhoff Gregory M	Chief Business Officer	C/O CENTESSA PHARMACEUTICALS PLC, 3RD FL., 1 ASHLEY RD, ALTRINCHAM, CHESHIRE, UNITED KINGDOM	/s/ Raphael Deferiere, attorney-in-fact	03 Feb 2026	0001400975

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CNTA	Ordinary Shares	Tax liability	$347,862	-14,158	-12%	$24.57	108,121	01 Feb 2026	Direct	F1, F2
transaction	CNTA	Ordinary Shares	Award	$0	+31,000	+29%	$0.000000	139,121	02 Feb 2026	Direct	F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CNTA	Share Option (right to buy)	Award	$0	+123,000		$0.000000	123,000	02 Feb 2026	Ordinary Shares	123,000	$25.19	Direct	F1, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2	Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of restricted share units.
F3	The shares reported in this transaction represent Restricted Share Units ("RSUs") issued under the Centessa Pharmaceuticals plc Amended and Restated 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one Ordinary Share of the Issuer. The RSUs shall vest and be settled in four equal annual installments with the first such annual vesting being on February 2, 2027.
F4	1/48th of the shares subject to such option shall vest and become exercisable in equal monthly installments with the first installment vesting on March 2, 2026.

Remarks:

Exhibit 24.2 - Substitute Power of Attorney